Evidence map›Paper›PMID 37439383›Full record

ArticleJournal of veterinary internal medicine

Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524.

Sally J Coggins, Jacqui M Norris, Richard Malik, Merran Govendir, Evelyn J Hall, Benjamin Kimble, Mary F Thompson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Feline Peritoneal Effusions-A Poor Prognosis?Animals : an open access journal from MDPI · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sally J CogginsSydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-8683-5014
Jacqui M NorrisSydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
Richard MalikCentre for Veterinary Education, The University of Sydney, NSW, Australia.
Merran GovendirSydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
Evelyn J HallSydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
Benjamin KimbleSydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
Mary F ThompsonSydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
The University of Sydney · AU

Funding

Cat Protection Society of NSWEveryCat Health Foundation W21-006EveryCat Health Foundation W21-018
6 · The paper itself

Abstract

backgroundNucleoside analog GS-441524 is effective in treating cats with feline infectious peritonitis (FIP). Investigation into the use of parent nucleotide analog remdesivir (GS-5734) is needed.

objectivesTo assess efficacy and tolerability of remdesivir with or without transition to GS-441524 in cats with FIP and document clinical and clinicopathologic progression over 6 months. ANIMALS: Twenty-eight client-owned cats with FIP.

methodsCats were prospectively recruited between May 2021 and May 2022. An induction dosage of remdesivir 10 to 15 mg/kg intravenously or subcutaneously q24h was utilized for 4 doses, with a maintenance dosage of remdesivir (6-15 mg/kg SC) or GS-441524 (10-15 mg/kg per os) every 24 hours continued for at least 84 days. Laboratory testing, veterinary, and owner assessments were recorded.

resultsTwenty-four cats survived to 6 months (86%). Three cats died within 48 hours. Excluding these, survival from 48 hours to 6 months was 96% (24/25). Remission was achieved by day 84 in 56% (14/25). Three cats required secondary treatment for re-emergent FIP. Remission was achieved in all 3 after higher dosing (15-20 mg/kg). Adverse reactions were occasional site discomfort and skin irritation with remdesivir injection. Markers of treatment success included resolution of pyrexia, effusions, and presenting signs of FIP in the first half of treatment and normalization of globulin concentration, and continued body weight gains in the latter half of the treatment period. CONCLUSIONS AND CLINICAL IMPORTANCE: Parenteral administration of remdesivir and oral administration of GS-441524 are effective and well-tolerated treatments for FIP. Early emphasis on clinical, and later emphasis on clinicopathologic response, appears prudent when monitoring treatment efficacy.

Indexed as

Cat DiseasesCoronavirus, FelineFeline Infectious PeritonitisAdenosineAdenosine MonophosphateAlanineAnimalsCatsExudates and TransudatesHumansAdenosineAdenosine MonophosphateAlanineGS-441524remdesivirantiviralclinical trialfeline coronavirusnucleoside analog

Identifiers

PMID37439383
PMCPMC10473006
OpenAlexW4384126414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.